LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

0.94

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.94

Max

0.99

Põhinäitajad
By Trading Economics
Sissetulek	3.6M -34M
Müük	278K 1.9M
Kasumimarginaal	-1,786.576
Töötajad	181
EBITDA	979K -37M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+338.54% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. nov 2025

Turustatistika
By TradingEconomics
Turukapital	3.8M 111M
Eelmine avamishind	0.94
Eelmine sulgemishind	0.94

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. sept 2025, 17:03 UTC

Suurimad hinnamuutused turgudel

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16. sept 2025, 16:49 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

GD Culture Shares Drop After Deal for Pallas Capital

16. sept 2025, 16:11 UTC

Suurimad hinnamuutused turgudel

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16. sept 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16. sept 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16. sept 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16. sept 2025, 21:10 UTC

Omandamised, ülevõtmised, äriostud

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16. sept 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16. sept 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16. sept 2025, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

16. sept 2025, 20:25 UTC

Tulu

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16. sept 2025, 20:24 UTC

Tulu

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16. sept 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16. sept 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16. sept 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16. sept 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16. sept 2025, 18:40 UTC

Omandamised, ülevõtmised, äriostud

Details Emerge on U.S.-China TikTok Deal -- WSJ

16. sept 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16. sept 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16. sept 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16. sept 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16. sept 2025, 16:53 UTC

Tulu

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16. sept 2025, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

16. sept 2025, 16:15 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Commodities Roundup: Market Talk

16. sept 2025, 16:09 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Energy Roundup: Market Talk

16. sept 2025, 16:09 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16. sept 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. sept 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16. sept 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16. sept 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

338.54% tõus

12 kuu keskmine prognoos

Keskmine 4.21 USD 338.54%

Kõrge 7 USD

Madal 2 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.